GlassScriptPhysician profile
Brijesh Goyal
NPI 1245247402
$2,730.95
in general payments reported to CMS, 2019-2025
28 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $234 · 2021: $493 · 2022: $549 · 2023: $534 · 2024: $254 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $764.33 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $232.41 | 2020-2025 | Rexulti |
| Corium, LLC | $218.75 | 2023 | Adlarity |
| Glaxosmithkline, LLC. | $186.97 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $186.03 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $154.11 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $135.07 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $118.39 | 2021 | |
| Lilly USA, LLC | $111.85 | 2019-2022 | |
| Amarin Pharma, INC. | $71.01 | 2020-2021 | |
| Ardelyx, INC. | $56.22 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $53.59 | 2019-2023 | Dificid |
| Inspire Medical Systems, INC. | $52.37 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $50.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.50 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $32.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.93 | 2020-2023 | |
| Medtronic, INC. | $31.64 | 2025 | Percept PC Brainsense |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.55 | 2021 | |
| Ucb, INC. | $26.05 | 2022 | |
| Axsome Therapeutics, INC. | $23.82 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.70 | 2019 | |
| Avanir Pharmaceuticals, INC. | $23.07 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.91 | 2021 | |
| Seqirus USA INC | $20.65 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Daiichi Sankyo INC. | $17.72 | 2024 | Injectafer |
| Vistapharm, INC. | $14.04 | 2021 | |
| Forte Bio-Pharma LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brijesh Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.